NEW YORK, July 1, 2016 /PRNewswire/ --
Market volatility and economic uncertainties are adding more pressure to firms in the Biotech arena, but opportunities are ever present in select companies. Take a look at today's featured equities on Stock-Callers.com and review their recent performances: Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), and Viking Therapeutics Inc. (NASDAQ: VKTX). Click below to receive your free trade alerts on these stocks and more:
To access Stock-Callers.com full PDF Research Packages for free, please visit the links below.
Full PDF DOWNLOAD Links
(You may have to copy and paste the links into your browser)
SNTA Research Package: http://stock-callers.com/registration/?symbol=SNTA
IDRA Research Package: http://stock-callers.com/registration/?symbol=IDRA
THLD Research Package: http://stock-callers.com/registration/?symbol=THLD
VKTX Research Package: http://stock-callers.com/registration/?symbol=VKTX
Lexington, Massachusetts-based Synta Pharmaceuticals Corp.'s shares saw a decline of 2.98%, closing Thursday's trading session at $0.26. The stock recorded a trading volume of 386,502 shares. Shares of the Company have advanced 4.08% in the previous three months. The stock is trading 27.96% below its 50-day moving average. Additionally, shares of Synta Pharmaceuticals, which focuses on the research, development, and commercialization of novel oncology medicines for cancer patients, have a Relative Strength Index (RSI) of 31.00.
On Thursday, shares in Cambridge, Massachusetts-based clinical-stage biopharmaceutical Company, Idera Pharmaceuticals Inc., recorded a trading volume of 597,494 shares. The stock edged 4.08% higher, ending the day at $1.53. The Company's shares are trading below their 50-day moving average by 0.87%. Furthermore, shares of Idera Pharmaceuticals, which focuses on the discovery, development, and commercialization of therapeutics for oncology and rare diseases in the U.S., have an RSI of 50.12.
South San Francisco, California headquartered clinical-stage biotechnology Company, Threshold Pharmaceuticals Inc.'s stock finished the day 9.55% higher at $0.64. A total volume of 2.96 million shares was traded, which was above their three months average volume of 1.03 million shares. The Company's shares have surged 35.19% in the last one month, 38.13% in the previous three months, and 32.38% on an YTD basis. The stock is trading above its 50-day moving average by 48.53%. Additionally, shares of Threshold Pharmaceuticals, which discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the U.S., have an RSI of 67.73.
Shares in San Diego, California headquartered clinical-stage biopharmaceutical Company, Viking Therapeutics Inc., ended yesterday's session 5.00% higher at $1.26. The stock recorded a trading volume of 82,827 shares. The Company's shares are trading 3.65% below their 50-day moving average. Moreover, shares in Viking Therapeutics, which focuses on the development of therapies for metabolic and endocrine disorders, have an RSI of 48.50.
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA